Skip to Main Content

446

Views

3

CrossRef citations to date

0

Altmetric

Original Articles

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma

David Yashara Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA;b Harbor-UCLA Medical Center, Carson, CA, USAView further author information

,

Tanya M. Spektorc Oncotherapeutics, West Hollywood, CA, USAView further author information

,

Daisy Martinezc Oncotherapeutics, West Hollywood, CA, USAView further author information

,

Matthew Ghermezic Oncotherapeutics, West Hollywood, CA, USAView further author information

,

Regina A. Swiftd James R. Berenson, MD, Inc., West Hollywood, CA, USAView further author information

,

Benjamin Eadesd James R. Berenson, MD, Inc., West Hollywood, CA, USAView further author information

,

Gary Schwartzd James R. Berenson, MD, Inc., West Hollywood, CA, USAView further author information

,

Shahrooz Eshaghiane Compassionate Oncology Medical Group, Los Angeles, CA, USAView further author information

,

Stephen Limf Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USAView further author information

,

Robert Vesciof Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USAView further author information

&

James R. Berensona Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA;c Oncotherapeutics, West Hollywood, CA, USA;d James R. Berenson, MD, Inc., West Hollywood, CA, USACorrespondence[email protected]
View further author information